Dyadic says C1 platform produces purified Ebola antigen or monoclonal antibody in about 15 days

Dyadic International, Inc.

Dyadic International, Inc.

DYAI

0.00
  • Dyadic highlighted rising demand for its C1 microbial protein platform tied to Bundibugyo Ebola virus preparedness and broader biologics manufacturing needs.
  • C1 has produced purified recombinant antigens or monoclonal antibodies in about 15 days from receipt of a codon-optimized viral gene sequence.
  • Collaboration with Scripps Research is evaluating faster development and production of vaccine antigens and monoclonal antibody candidates for Ebola and other emerging viruses.
  • Separate CEPI Ebola funding-call proposals incorporate C1 for rapid antigen development and scalable vaccine manufacturing.
  • DYAI-100 clinical study showed C1-produced antigens were generally safe and well tolerated, supporting recombinant protein vaccine applications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150725PRIMZONEFULLFEED9746925) on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.